{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T13:58:02Z","timestamp":1769090282386,"version":"3.49.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-023-02532-6","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T17:05:18Z","timestamp":1674147918000},"page":"1533-1539","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prevalence of adverse events varies with the different oral isotretinoin brands in acne treatment: a retrospective observational study"],"prefix":"10.1007","volume":"315","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3906-7021","authenticated-orcid":false,"given":"Boutros","family":"Soutou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joelle","family":"Sleiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Tomb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elio","family":"Kechichian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josiane","family":"Helou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,19]]},"reference":[{"key":"2532_CR1","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","volume":"74","author":"AL Zaenglein","year":"2016","unstructured":"Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, Bowe WP, Graber EM, Harper JC, Kang S, Keri JE, Leyden JJ, Reynolds RV, Silverberg NB, Stein Gold LF, Tollefson MM, Weiss JS, Dolan NC, Sagan AA, Stern M, Boyer KM, Bhushan R (2016) Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 74:945\u2013973","journal-title":"J Am Acad Dermatol"},{"key":"2532_CR2","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1111\/exd.13787","volume":"27","author":"NF Agamia","year":"2018","unstructured":"Agamia NF, Hussein OM, Abdelmaksoud RE, Abdalla DM, Talaat IM, Zaki EI, El Tawdy A, Melnik BC (2018) Effect of oral isotretinoin on the nucleo-cytoplasmic distribution of FoxO1 and FoxO3 proteins in sebaceous glands of patients with acne vulgaris. Exp Dermatol 27:1344\u20131351","journal-title":"Exp Dermatol"},{"key":"2532_CR3","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1038\/sj.jid.5700289","volume":"126","author":"AM Nelson","year":"2006","unstructured":"Nelson AM, Gilliland KL, Cong Z, Thiboutot DM (2006) 13-cis Retinoic acid induces apoptosis and cell cycle arrest in human SEB-1 sebocytes. J Investig Dermatol 126:2178\u20132189","journal-title":"J Investig Dermatol"},{"key":"2532_CR4","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/dth.12084","volume":"26","author":"SC On","year":"2013","unstructured":"On SC, Zeichner J (2013) Isotretinoin updates. Dermatol Ther 26:377\u2013389","journal-title":"Dermatol Ther"},{"key":"2532_CR5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/bjd.15668","volume":"178","author":"IA Vallerand","year":"2018","unstructured":"Vallerand IA, Lewinson RT, Farris MS, Sibley CD, Ramien ML, Bulloch AGM, Patten SB (2018) Efficacy and adverse events of oral isotretinoin for acne: a systematic review. Br J Dermatol 178:76\u201385","journal-title":"Br J Dermatol"},{"issue":"4","key":"2532_CR6","doi-asserted-by":"publisher","first-page":"e12483","DOI":"10.1111\/dth.12483","volume":"30","author":"P Brzezinski","year":"2017","unstructured":"Brzezinski P, Borowska K, Chiriac A, Smigielski J (2017) Adverse effects of isotretinoin: a large, retrospective review. Dermatol Ther 30(4):e12483. https:\/\/doi.org\/10.1111\/dth.12483","journal-title":"Dermatol Ther"},{"key":"2532_CR7","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.ijwd.2020.07.004","volume":"6","author":"P Chelliah","year":"2020","unstructured":"Chelliah P, Glass D (2020) Comprehensive review of reports of menstrual irregularities associated with isotretinoin. Int J Womens Dermatol 6:365\u2013367","journal-title":"Int J Womens Dermatol"},{"key":"2532_CR8","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1038\/ajg.2009.334","volume":"104","author":"SD Crockett","year":"2009","unstructured":"Crockett SD, Gulati A, Sandler RS, Kappelman MD (2009) A causal association between isotretinoin and inflammatory bowel disease has yet to be established. Am J Gastroenterol 104:2387\u20132393","journal-title":"Am J Gastroenterol"},{"key":"2532_CR9","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.jaad.2016.12.028","volume":"76","author":"YC Huang","year":"2017","unstructured":"Huang YC, Cheng YC (2017) Isotretinoin treatment for acne and risk of depression: a systematic review and meta-analysis. J Am Acad Dermatol 76:1068-1076.e9","journal-title":"J Am Acad Dermatol"},{"key":"2532_CR10","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1001\/archderm.1996.03890310053007","volume":"132","author":"DJ Margolis","year":"1996","unstructured":"Margolis DJ, Attie M, Leyden JJ (1996) Effects of isotretinoin on bone mineralization during routine therapy with isotretinoin for acne vulgaris. Arch Dermatol 132:769\u2013774","journal-title":"Arch Dermatol"},{"key":"2532_CR11","first-page":"CD009435","volume":"11","author":"CS Costa","year":"2018","unstructured":"Costa CS, Bagatin E, Martimbianco ALC, da Silva EM, L\u00facio MM, Magin P, Riera R (2018) Oral isotretinoin for acne. Cochrane Database Syst Rev 11:CD009435","journal-title":"Cochrane Database Syst Rev"},{"key":"2532_CR12","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1067\/mjd.2001.115966","volume":"45","author":"JS Strauss","year":"2001","unstructured":"Strauss JS, Leyden JJ, Lucky AW, Lookingbill DP, Drake LA, Hanifin JM, Lowe NJ, Jones TM, Stewart DM, Jarratt MT, Katz I, Pariser DM, Pariser RJ, Tschen E, Chalker DK, Rafal ES, Savin RP, Roth HL, Chang LK, Baginski DJ, Kempers S, McLane J, Eberhardt D, Leach EE, Bryce G, Hong J (2001) Safety of a new micronized formulation of isotretinoin in patients with severe recalcitrant nodular acne: a randomized trial comparing micronized isotretinoin with standard isotretinoin. J Am Acad Dermatol 45:196\u2013207","journal-title":"J Am Acad Dermatol"},{"key":"2532_CR13","first-page":"665","volume":"13","author":"GF Webster","year":"2014","unstructured":"Webster GF, Leyden JJ, Gross JA (2014) Results of a phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne. J Drugs Dermatol 13:665\u2013670","journal-title":"J Drugs Dermatol"},{"key":"2532_CR14","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1185\/030079906X96326","volume":"22","author":"PW Taylor","year":"2006","unstructured":"Taylor PW, Keenan MHJ (2006) Pharmaceutical quality of generic isotretinoin products, compared with Roaccutane. Curr Med Res Opin 22:603\u2013615","journal-title":"Curr Med Res Opin"},{"key":"2532_CR15","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/j.1440-0960.2010.00657.x","volume":"51","author":"M Rademaker","year":"2010","unstructured":"Rademaker M (2010) Adverse effects of isotretinoin: a retrospective review of 1743 patients started on isotretinoin. Australas J Dermatol 51:248\u2013253","journal-title":"Australas J Dermatol"},{"key":"2532_CR16","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1001\/jamadermatol.2013.6746","volume":"149","author":"RC Blasiak","year":"2013","unstructured":"Blasiak RC, Stamey CR, Burkhart CN, Lugo-Somolinos A, Morrell DS (2013) High-dose isotretinoin treatment and the rate of retrial, relapse, and adverse effects in patients with acne vulgaris. JAMA Dermatol 149:1392","journal-title":"JAMA Dermatol"},{"key":"2532_CR17","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jaad.2017.09.078","volume":"78","author":"DM Thiboutot","year":"2018","unstructured":"Thiboutot DM, Dr\u00e9no B, Abanmi A, Alexis AF, Araviiskaia E, Barona Cabal MI, Bettoli V, Casintahan F, Chow S, da Costa A, El Ouazzani T, Goh CL, Gollnick HPM, Gomez M, Hayashi N, Herane MI, Honeyman J, Kang S, Kemeny L, Kubba R, Lambert J, Layton AM, Leyden JJ, L\u00f3pez-Estebaranz JL, Noppakun N, Ochsendorf F, Oprica C, Orozco B, Perez M, Piquero-Martin J, See JA, Suh DH, Tan J, Lozada VT, Troielli P, Xiang LF (2018) Practical management of acne for clinicians: an international consensus from the global alliance to improve outcomes in acne. J Am Acad Dermatol 78:S1\u2013S23","journal-title":"J Am Acad Dermatol"},{"key":"2532_CR18","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s40257-020-00508-0","volume":"21","author":"MN Landis","year":"2020","unstructured":"Landis MN (2020) Optimizing isotretinoin treatment of acne: update on current recommendations for monitoring, dosing, safety, adverse effects, compliance, and outcomes. Am J Clin Dermatol 21:411\u2013419","journal-title":"Am J Clin Dermatol"},{"key":"2532_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/1203475415595776","volume":"20","author":"J Tan","year":"2016","unstructured":"Tan J, Knezevic S, Boyal S, Waterman B, Janik T (2016) Evaluation of evidence for acne remission with oral isotretinoin cumulative dosing of 120\u2013150 mg\/kg. J Cutan Med Surg 20:13\u201320","journal-title":"J Cutan Med Surg"},{"key":"2532_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1001\/jamadermatol.2015.3091","volume":"152","author":"YH Lee","year":"2016","unstructured":"Lee YH, Scharnitz TP, Muscat J, Chen A, Gupta-Elera G, Kirby JS (2016) Laboratory monitoring during isotretinoin therapy for acne: a systematic review and meta-analysis. JAMA Dermatol 152:35\u201344","journal-title":"JAMA Dermatol"},{"key":"2532_CR21","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jaad.2019.06.025","volume":"82","author":"JS Barbieri","year":"2020","unstructured":"Barbieri JS, Shin DB, Wang S, Margolis DJ, Takeshita J (2020) The clinical utility of laboratory monitoring during isotretinoin therapy for acne and changes to monitoring practices over time. J Am Acad Dermatol 82:72\u201379","journal-title":"J Am Acad Dermatol"},{"key":"2532_CR22","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1001\/jamadermatol.2022.2044","volume":"158","author":"E Xia","year":"2022","unstructured":"Xia E, Han J, Faletsky A, Baldwin H, Beleznay K, Bettoli V, Dr\u00e9no B, Goh CL, Stein Gold L, Gollnick H, Herane MI, Kang S, Kircik L, Mann J, Nast A, Oon HH, See JA, Tollefson M, Webster G, Zip C, Tan J, Tapper EB, Thiboutot D, Zaenglein A, Barbieri J, Mostaghimi A (2022) Isotretinoin laboratory monitoring in acne treatment: a Delphi Consensus study. JAMA Dermatol 158:942\u2013948","journal-title":"JAMA Dermatol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-023-02532-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-023-02532-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-023-02532-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T16:06:26Z","timestamp":1689177986000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-023-02532-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,19]]},"references-count":22,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["2532"],"URL":"https:\/\/doi.org\/10.1007\/s00403-023-02532-6","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,19]]},"assertion":[{"value":"26 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have stated explicitly that there are no conflicts of interest in connection with this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the institution\u2019s IRB committee (Reference Number: Tfem\/2022\/78).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"No photos of patients included.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}